Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07005986
Recruiting Not applicable

Role of Circulating Pyrophosphate as a Biomarker of Mediacalcinosis in Type 2 Diabetic Patients

NCT07005986 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Universitaire de Nice
Phase
Not applicable
Started
2025-06-18
Last updated
2025-07-10

Condition(s) studied

Type 2 DiabetesType 2 Diabetes Patients

Investigational drug(s) / intervention(s)

Plasmatic PPi level

Plasmatic PPi level: Plasmatic PPi level dosage at visit 1

Study summary

Type 2 diabetes currently affects around 4 million people in France, with the number of cases rising steadily. Complications of T2DM are essentially cardiovascular. In particular, T2DM is associated with calcification of peripheral vessel walls (mediacalcosis), responsible for increased vascular stiffness. This calcium deposition is known to be a cardiovascular risk factor, but the mechanism of its deposition in relation to diabetes is not clearly established. An important blood compound, inorganic pyrophosphate (PPi), which is the body's natural anti-calcifier is impacted in some way in T2DM. PPi is degraded by alkaline phosphatase (ALP), and is produced by an enzyme called ENPP1. ENPP1 activity is decreased and APL activity increased in insulin-resistant subjects, which could contribute to a decrease in tissue and circulating PPi, and thus favor a tissue pro-calcifying balance. We propose to test this hypothesis in a pilot study characterizing plasma PPi levels, in relation to ENPP1 activity, in type 2 diabetic patients. The aim of the study is also to determine if there is a link between blood PPi levels and the progression of calcifications in arteries.

Eligibility

Sex
MALE
Min age
40 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: 1. Adult men (between 40 and 70 years of age). 2. T2DM defined according to ADA or HAS criteria, evolving for more than 6 months, may be : - Not complicated * Complicated by diabetic retinopathy and/or diabetic nephropathy (creatinine clearance \> 60 ml/min) and/or peripheral arterial disease and/or ischemic heart disease and/or stroke. - With dyslipidemia (LDLc \> 1.90) and/or a history of past or active smoking. * Balanced with HbA1c \< 8% according to patient's personalized objectives, or unbalanced with HbA1c \> 9%. * Treated with insulin therapy (single or multi-injections) or not. - Whose treatment includes at least one iSGLT2. 3. Member of 'Sécurité Sociale" Exclusion Criteria: 1. Patient already included in another study. 2. Patient in a particular situation judged incompatible with the study by the investigator. 3. Patient living in a department other than Alpes-Maritimes or Var. 4. Patient refusing to give consent. 5. Patient deprived of liberty by administrative or judicial decision, under guardianship or curatorship. 6. Patient with decompensated hepatic cirrhosis (Child C and above, score 10 to 15 points). 7. Patients with chronic kidney disease (from stage 3, i.e. GFR \< 59 ml/min/1.73 m2). 8. Patient with a recent fracture (within the last 3 months). 9. Patient treated with AVK or biphosphonates. 10. Patient with known, treated osteoporosis. 11. Patient with unsupplemented vitamin D deficiency. 12. Patient with active cancer. 13. Patient with an active inflammatory pathology.

Primary outcome measure(s)

  • Measurement of plasma inorganic pyrophosphate level — Blood samples are taken during first visit, in the morning, after fasting
    Measurement of plasma inorganic pyrophosphate level in Type 2 diabetes patients and comparaison with a laboratory reference value

Trial sites (1)

FacilityCityRegionStatus
CHU de Nice Nice France Recruiting

More Centre Hospitalier Universitaire de Nice trials in France

AI-enhanced Imaging Analysis to Predict Post-EVAR Starting soon
Robotic Emergency General Surgery Program Starting soon
Comparison of Arterial and Capillary Blood Gas Analyses in Patients With Respiratory Distress Due to COPD or APE Recruiting
Videographic Feedback and Walk Rehabilitation in Post-Cerebrovascular Accident Recruiting
Home Based Personalized Training and Video Consultation in Mitochondrial Myopathies: Study of Efficacy and Tolerance. Recruiting

Other trials for the same condition

Insulin Pump Versus Full Closed-loop for Type 2 Diabetes Recruiting
Fecal Microbiota Transfer to Improve Diabetes Control Post-bariatric Surgery Recruiting
Evaluation of the Impact of Psychological Profile on Diabetic Foot Wound Healing. Recruiting
Lactic Acidosis and Prior Metformin Treatment Recruiting
Trancriptomics and Lipidomics of Epicardial Ectopic Fat Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07005986 on ClinicalTrials.gov ↗ ← All trials in France